Deciphera Pharmaceuticals (NASDAQ:DCPH) and Intec Pharma (NASDAQ:NTEC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
Risk and Volatility
Deciphera Pharmaceuticals has a beta of 2.65, indicating that its share price is 165% more volatile than the SP 500. Comparatively, Intec Pharma has a beta of 0.49, indicating that its share price is 51% less volatile than the SP 500.
This table compares Deciphera Pharmaceuticals and Intec Pharma’s net margins, return on equity and return on assets.
This is a summary of recent recommendations for Deciphera Pharmaceuticals and Intec Pharma, as provided by MarketBeat.
Deciphera Pharmaceuticals currently has a consensus target price of $46.29,